title: Behavioural activation v. antidepressant medication for treating depression in Iran: randomised trial.
abstract: BACKGROUND
  Behavioural activation might be a viable alternative to antidepressant medication for major depressive disorder.
  
  
  OBJECTIVE
  To compare the effectiveness of behavioural activation and treatment as usual (TAU, antidepressant medication) for major depressive disorder in routine clinical practice in Iran.
  
  
  METHODS
  Patients with major depressive disorder (n = 100) were randomised to 16 sessions of behavioural activation (n = 50) or antidepressant medication (n = 50) (IRCT138807192573N1). The main outcome was depression, measured with the Beck Depression Inventory (BDI) and the Hamilton Rating Scale for Depression (HRSD), assessed at 0, 4, 13 and 49 weeks.
  
  
  RESULTS
  Symptom reduction was greater in the behavioural activation group than in the TAU group on both the BDI and the HRSD at 13 and 49 weeks in multilevel analysis. Baseline depression severity was a moderator, with relatively better effects for behavioural activation in individuals who were more severely depressed. Also, there was better retention in the behavioural activation than in the TAU group.
  
  
  CONCLUSIONS
  Behavioural activation is a viable and effective treatment for people with major depressive disorder, especially for those who are more severely depressed, and it can successfully be disseminated into routine practice settings in a non-Western country such as Iran.
authors: Department of Clinical Psychological Science, Faculty of Psychology and Neuroscience, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors: Latif
authors: L
authors: Moradveisi
authors: Marcus J H
authors: MJ
authors: Huibers
authors: Fritz
authors: F
authors: Renner
authors: Modabber
authors: M
authors: Arasteh
authors: Arnoud
authors: A
authors: Arntz
mesh_terms: D000223:Adaptation, Psychological; D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001521:Behavior Therapy / Q000379:methods*; D003865:Major Depressive Disorder / Q000628:therapy*; D005260:Female; D006801:Humans; D057194:Intention to Treat Analysis; D007492:Iran; D008297:Male; D008875:Middle Aged; D055361:Multilevel Analysis; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D020280:Sertraline / Q000627:therapeutic use*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D020280:Sertraline